After listening to today’s webcast describing the Brookwood acquisition, I have come to believe that SRDX added glaucoma to their list of relevant ocular diseases on their website to reflect Brookwood’s initiatives. I had originally thought that it might foreshadow details concerning the Merck agreement.
By the way, I thought that the Brookwood webcast was informative and worth listening to (see the SRDX webpage for link).
Market Data 
Markets 
AI
